Skip to content

the effect of probiotic supplement and soy milk in diabetic

Assessment of the effect of probiotic supplement and soy milk on lipid profiles, Blood sugar, insulin resistance status and blood pressure in diabetic patients type II

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015080423495N1
Enrollment
100
Registered
2016-01-22
Start date
2015-10-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Non-insulin-dependent diabetes mellitus

Interventions

Intervention 1: Intervention group: soy milk+probiotic cap , a glass of milk ( and a capsule every day for 6 weeks. Intervention 2: Intervention group: soy milk+placebo cap , a glass of milk and a ca
milk + placebo , a glass of milk and a capsule every day for 6 weeks.
Treatment - Other
Intervention group: soy milk+probiotic cap , a glass of milk ( and a capsule every day for 6 weeks
Intervention group: soy milk+placebo cap , a glass of milk and a capsule every day for 6 weeks
Intervention group: probiotic cap , a capsule every day for 6 weeks
Control group
milk + placebo , a glass of milk and a capsule every day for 6 weeks

Sponsors

Vice Chancellor for Research of Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria : having willingness to cooperate in the plan and presenting the written consent form ; being 75-40 years old ; diagnosis of diabetes based on a specialist opinion ; being residence of Fars province ; having the ability to understand the objectives of the study Exclusion criteria : any acute and chronic disease that cause patients not to be able to follow research protocols ; consumption of foods and products that contain probiotic bacteria 3 weeks before the start of the intervention and during the intervention ; Change in dose of drug or insulin ; using drugs that lower the blood sugar ; blood pressure and blood fat during the intervention ; use of antibiotics ; the incidence of severe side effects and failure to follow the diet ; non-compliance with the study protocol.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Fasting blood sample. Timepoint: The beginning and end of the intervention. Method of measurement: measured by enzymatic spectrophotometry analysis.;Blood pressure. Timepoint: Early intervention-Every tree weeks, once-End of intervention. Method of measurement: mmHg,with an automatic sphygmomanometer.;Lipid profile. Timepoint: The beginning and end of the intervention. Method of measurement: measured by enzymatic spectrophotometry analysis.;Weight. Timepoint: Early intervention-Every tree weeks, once-End of intervention. Method of measurement: seca Scale.;Insulin. Timepoint: The beginning and end of the intervention. Method of measurement: ELISA.

Secondary

MeasureTime frame
Body mass index. Timepoint: The beginning and end of the intervention. Method of measurement: Measured height and weight.;Insulin resistant. Timepoint: The beginning and end of the intervention. Method of measurement: HOMA-IR.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Siavash Babajafari

Shiraz University Of Medical Sciences

jafaris@sums.ac.ir+98 71 3725 1001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026